Navigation Links
TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
Date:6/25/2008

TorreyPines Therapeutics' CEO Neil Kurtz, M.D., to Moderate Discussion Following Presentations by Tony Yaksh, Ph.D.; Jerome Goldstein, M.D.; and

Alan J. Tuchman, M.D.

LA JOLLA, Calif., June 25 /PRNewswire/ -- A Webinar hosted by TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) at 11 a.m. EDT on June 25 will bring together industry experts to discuss the opportunity of treating chronic pain, migraine and muscle spasticity through the inhibition of the neurotransmitter glutamate.

The company's President and Chief Executive Officer, Neil Kurtz, M.D., will moderate a discussion following brief presentations by:

-- Tony Yaksh, Ph.D., Professor and Vice Chairman for Research, Department of Anesthesiology, and Professor of Pharmacology at the University of California, San Diego

Dr. Yaksh will present information about glutamate receptors in the

central nervous system as a target for chronic pain therapy. The focus

of his research is the physiology and pharmacology of pain processing.

A member of numerous professional societies, Dr. Yaksh has been a

consultant to the U.S. Food and Drug Administration and serves on the

editorial boards of several journals. He has received many awards,

including the FWL Kerr Award from the American Pain Society and the

American Society of Anesthesiology Award for Excellence in Research.

-- Jerome Goldstein, M.D., Director of the San Francisco Headache Clinic and a board-certified neurologist who focuses on the diagnosis, treatment, prevention and cure of headache

Dr. Goldstein will present information about glutamate receptors in

the brain as a target for acute and prophylactic migraine therapy. He

is a member of the American Headache Society, The International

Headache Society and The National Headache Foundation. Dr. Goldstein

is a Board Certified Neurologist, a Fellow of the American Academy of

Neurology, and has special qualification for the treatment of headache

from the National Headache Foundation. He has received many industry

awards, published articles in industry journals and served on advisory

boards related to the development of a wide range of headache

therapies.

-- Alan J. Tuchman, M.D., Clinical Professor of Neurology and Pharmacology at New York Medical College, Principal of a neuroscience-focused consulting firm and a board-certified neurologist

Dr. Tuchman will present information about glutamate receptors in the

spinal cord as a target for muscle spasticity. He has served as Vice

Chairman of the Department of Neurology at New York Medical College as

well as Vice Dean of Clinical Affairs, which involved the development

and management of clinical care and medical education policy for 29

affiliated hospitals. In addition, he was President of the Epilepsy

Society of Southern New York. Dr. Tuchman is a frequent speaker about

neuroscience topics at academic meetings.

"There's a growing body of scientific and clinical evidence that supports the further development of drugs that block the glutamate cascade," said Dr. Kurtz. "As the American Headache Society prepares to kick off its 50th Annual Scientific Meeting, we want to provide patients as well as the medical community with industry experts' perspectives as to what is clearly a promising approach for the treatment of migraine and other conditions."

TorreyPines Therapeutics' lead compound, tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for chronic pain. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis.

Webinar Information

Participants can access the Webinar by clicking on the link located on the home page of TorreyPines Therapeutics' Web site at http://www.torreypinestherapeutics.com. Individuals interested in asking questions should also participate via telephone by calling 888-823-7457 in the United States or 973-935-8504 outside of the United States and entering conference ID 48658866. Participants are encouraged to log on at least 15 minutes prior to the beginning of the Webinar. A replay of the Webinar will be available on TorreyPines Therapeutics' Web site until July 25.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel and NGX426 as treatments for migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials conducted in the future, will prove successful, and if successful, whether the results can be replicated. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
3. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
6. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
7. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... -- The U.S. Food and Drug Administration today approved Trulance ... adult patients. "No one medication works for ... Beitz , M.D., director of the Office of Drug Evaluation ... "With the availability of new therapies, patients and their doctors ... ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... 2017 , ... Medical lab testing through hospitals and other traditional ... test will take days to arrive to the end customer, having to travel through ... their lab tests, bypassing the cost and delay of traditional means. Now all employees ...
(Date:1/21/2017)... ... ... Salveo for life, a company that distributes an effervescent lime-flavored drink called ... part of its presence to expand its market reach. , Using a formula developed ... nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst supporting ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of ... vision of its owner and founder. As Oat is recognized globally as one of ... knows personally as he believes it is a move to sow the seed of ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate ... the electrifying line-up of events for its annual meeting “Coming Home 2017,” an ... “Coming Home 2017” will be held on Friday January 27 through Sunday, ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... the opening of its new medical office in Petaluma, located at 167 Lynch ... casting room, access to SRO sports medicine and rehabilitation services and ...
Breaking Medicine News(10 mins):